hotspot -WSS

hotspot

author：comprehensive 2025-09-29 20:51:20 - browse：27

ADAM FEUERSTEIN/STAT

CHICAGO — Corbus Pharmaceuticals is the second best-performing biotech stock this year, thanks to investor interest in an antibody-drug conjugate candidate, or ADC, called CRB-701 with the potential to be better tolerated than Padcev, an ADC treatment bladder cancer that Pfizer acquired as part of its $43 billion Seagen deal.

On Saturday, Corbus updated results from an early, dose-finding study of CRB-701, showing an overall response rate of 28% from 25 evaluable patients. Closer attention is being paid to the subset of 15 patients treated at three therapeutically active doses, where the overall response rate (all partial tumor shrinkage) was 40%. All of the responses were seen in bladder cancer (where Padcev is approved) and in cervical cancer.

The data, from a study conducted in China, were presented in a poster session at the annual meeting of the American Society of Clinical Oncology.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Mass General totes up its waste in a move to tackle climate change

hotspot

Wikipedia

WSS

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

Tocagen's brain cancer gene therapy trial continues. Investors worry

Stanford president's case begs question: Who takes blame?

After traumatic brain injury, life support decisions can use more time

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

Wikipedia

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Tori Bowie and the unacceptable rates of Black maternal death

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

At least 13 dead in Texas as scorching temps continue

Judge rejects Trump's request to move Stormy Daniels hush

Drug repurposing or repositioning? The language matters

Getting Alzheimer's drug Leqembi to patients can be a challenge

Tori Bowie and the unacceptable rates of Black maternal death

UnitedHealth financials solid despite Change Healthcare cyberattack

Trump demands the U.S. pay no more for drugs than other countries … again

Wildfires rage amid heat wave in Greece, prompting evacuations and call for European support

focus

Wildfires rage amid heat wave in Greece, prompting evacuations and call for European support

Stanford president's case begs question: Who takes blame?

Close Medicare's dangerous gaps in addiction treatment coverage

Exact Sciences stock tumbles despite strong cancer detection sales

Indian pharmaceutical industry in denial over drug

Stanford president's case begs question: Who takes blame?

focus

hotspot

Wikipedia

knowledge